Records of COPD patients with two respiratory cultures yielding Aspergillus were retrospectively reviewed. Cases categorized as proven/probable IPA or colonization was analyzed.
118 patients were identified: 70 (59.3 % ) colonized, 48 (40.7 % ) with IPA (42 probable, 6 proven). Higher percentage of IPA patients (vs. colonized) presented GOLD III?+?IV (77.1 % vs. 57.1 % , p?=?0.025). IPA patients presented higher Charlson index (3.5?¡À?2.5 vs. 2.6?¡À?2.2, p?=?0.027), higher rate of ICU admission (27.1 % vs. 4.3 % , p?=?0.001) and worse prognosis (McCabe rapidly fatal category: 31.3 % vs. 7.1 % , p?=?0.001). GOLD-I IPA patients presented risk factors other than COPD. Before hospitalization, 66.7 % IPA and 28.6 % colonized patients were taking steroids (p?<?0.001). Antifungals were administered to 83.3 % IPA and 21.4 % colonized patients (p?<?0.001). Mortality was higher among IPA vs. colonized patients, both in global (58.3 % vs. 10.0 % , p?<?0.001), GOLD-I (75.0 % vs. 10.0 % , p?=?0.041), GOLD-II (42.9 % vs. 5.0 % , p?=?0.042) and GOLD-III patients (54.2 % vs. 0.0 % , p?<?0.001), but not in GOLD-IV patients (69.2 % vs. 31.3 % , p?=?0.066).
IPA should be suspected not only in GOLD-III and GOLD-IV COPD patients, with higher mortality in IPA vs. colonized patients for GOLD-II and -III COPD patients.